ABSTRACT
Sarcomas of the large vessels usually present centrally in the aorta, pulmonary artery, and inferior vena cava. Peripheral arterial sarcomas are exceptionally rare. They have been reported in the iliac and common or profunda femoral arteries, and are frequently undifferentiated. In this study, we describe a differentiated intimal sarcoma of the superficial femoral artery with abundant osteosarcoma within the specimen. Before knowing the diagnosis, treatment was for a presumed pseudoaneurysm using excision and bypass. Postoperatively, the patient received palliative radiation therapy. The tumor's location and histopathology are unique. A differentiated intimal sarcoma has never been reported in the superficial femoral artery, and it represents the second peripheral arterial intimal sarcoma reported with osteosarcomatous differentiation.
Subject(s)
Cell Differentiation , Femoral Artery/pathology , Osteosarcoma/pathology , Sarcoma/pathology , Tunica Intima/pathology , Vascular Neoplasms/pathology , Aged, 80 and over , Aneurysm, False/diagnosis , Biopsy , Diagnostic Errors , Fatal Outcome , Femoral Artery/radiation effects , Femoral Artery/surgery , Humans , Immunohistochemistry , Magnetic Resonance Angiography , Osteosarcoma/therapy , Palliative Care , Radiotherapy, Adjuvant , Sarcoma/therapy , Treatment Outcome , Tunica Intima/radiation effects , Tunica Intima/surgery , Vascular Neoplasms/therapy , Vascular Surgical ProceduresSubject(s)
Hidrocystoma/diagnosis , Hidrocystoma/drug therapy , Sweat Gland Neoplasms/diagnosis , Sweat Gland Neoplasms/drug therapy , Aminolevulinic Acid/administration & dosage , Diagnosis, Differential , Face , Hidrocystoma/pathology , Humans , Male , Middle Aged , Photochemotherapy , Photosensitizing Agents/administration & dosage , Sweat Gland Neoplasms/pathologyABSTRACT
Blood testing for biomarkers of myocardial injury plays an increasingly important role for the evaluation, diagnosis, and triage of patients with chest pain. The guidelines for the diagnosis of myocardial infarction (MI) have recently changed and prominently incorporate the results of cardiac marker testing in the clinical definition of MI. We review these updated guidelines for MI definition as it pertains to cardiac biomarker testing and further compare the differing biology and release kinetics of clinically relevant biomarkers. Finally, we define the contemporary use of cardiac biomarker testing for patients with chest pain, including appropriate integration of point-of-care testing into day-to-day clinical use.
